

A large graphic on the left side of the slide consisting of two overlapping chevron shapes. The top chevron is yellow and points downwards, containing the text 'ECHO IDAHO' in white. The bottom chevron is light gray and points upwards.

ECHO IDAHO

Small Device, Big Impact: The Power of Proper Inhaler Use

August 19, 2025

Camille Stover, MET, RRT, RRT-NPS

Clinical Associate Professor, Entry-to-Practice Program Director

Boise State University – Department of Respiratory Care

None of the planners or presenters for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.



University of Idaho
School of Health and Medical
Professions



Learning Objectives

- Review types of inhaled respiratory medication delivery devices
- List requirements for effective medication delivery
- Identify proper techniques for using different types of inhaled medication delivery devices
- Explain how to properly use various delivery devices for patients
- Share resources for navigating insurance and access issues

Disclosures

- I do not receive any financial benefit from the products I mention
- Medication images ≠ Camille's recommendation
- The In-Check Dial is the only available tool that I am aware of at this time

THANK YOU!




Why are we here?

6.2% of Idahoans have COPD ¹

10.5% of Idahoans have Asthma ¹

Idaho has the fewest PCPs in the US²



1. America's Health Rankings
2. American Medical Association Physician Masterfile

Inhaled Medications

- Topical medications used to treat a variety of respiratory diseases
- Fine particles enter the airways
- Fall out of suspension and deposit on airways

SHORT-ACTING BETA₂-AGONIST (SABA) BRONCHODILATORS

relax tight muscles in airways and offer quick relief of symptoms such as coughing, wheezing and shortness of breath for 3-6 hours

Albuterol Sulfate Inhalation Solution
0.63, 1.25 mg, 2.5mg; 3 mL
A B N



ProAir RespiClick®
90 mcg
albuterol sulfate inhalation powder
A



Proventil® HFA
90 mcg
albuterol sulfate
A G



Ventolin® HFA
90 mcg
albuterol sulfate
A G



Xopenex®
0.31, 0.63, 1.25 mg; 3 mL
levalbuterol hydrochloride inhalation solution
A B N



Xopenex HFA®
45 mcg
levalbuterol tartrate
A G



SABA and ICS contains SABA to relax airway muscles and offer quick relief of symptoms, and inhaled corticosteroid (ICS) to reduce inflamed airways

AIRSUPRA®
90/80 mcg
albuterol and budesonide
A



INHALED CORTICOSTEROIDS (ICS)

reduce and prevent swelling of airway tissue; they do not relieve sudden symptoms of coughing, wheezing or shortness of breath

Alvesco® HFA
80, 160 mcg
ciclesonide
A



Arnuity® Ellipta®
50, 100, 200 mcg
fluticasone furoate inhalation powder
A



Asmanex® HFA
50, 100, 200 mcg
mometasone furoate
A



Asmanex® Twisthaler®
110, 220 mcg
mometasone furoate inhalation powder
A



Fluticasone Propionate Diskus Inhalation Powder
50, 100, 250 mcg
authorized generic of Flovent Diskus
A



Fluticasone Propionate HFA
44, 110, 220 mcg
authorized generic of Flovent HFA
A



Pulmicort Flexhaler®
90, 180 mcg
budesonide inhalation powder
A



Pulmicort Respules®
0.25, 0.50, 1.0 mg; 2 mL
budesonide inhalation suspension
A B N



QVAR Redihaler®
40, 80 mcg
beclomethasone dipropionate
A



LONG-ACTING BETA₂-AGONIST (LABA) BRONCHODILATORS

relax tight muscles in airways and offer lasting relief of symptoms such as coughing, wheezing and shortness of breath for at least 12 hours

Brovana®
15 mcg; 2 mL
arformoterol tartrate inhalation solution
C N



Perforomist®
20 mcg; 2 mL
formoterol fumarate inhalation solution
C N



Serevent® Diskus®
50 mcg
salmeterol xinafoate inhalation powder
A C



Striverdi® RespiMat®
2.5 mg
olodaterol hydrochloride
C



MUSCARINIC ANTAGONISTS (ANTICHOLINERGICS)

relieve cough, sputum production, wheeze and chest tightness associated with chronic lung diseases

SHORT-ACTING

Atrrovent® HFA
17 mcg
ipratropium bromide
C



LONG-ACTING

Incruse® Ellipta®
62.5 mcg
umeclidinium inhalation powder
C




Ipratropium Bromide Inhalation Solution
0.5/3 mg; 3 mL
C B N



Spiriva® HandiHaler®
18 mcg
tiotropium bromide inhalation powder
C



Spiriva® RespiMat®
1.25, 2.5 mcg
tiotropium bromide
A C



Tudorza® Pressair®
400 mcg
acridinium bromide inhalation powder
C



Yupelri®
175 mcg; 3 mL
revefenacin inhalation solution
C N



COMBINATION MEDICATIONS

contain ICS and LABA

Advair Diskus®
100/50, 250/50, 500/50 mcg
fluticasone propionate and salmeterol inhalation powder
A C G



Advair® HFA
45/21, 115/21, 230/21 mcg
fluticasone propionate and salmeterol xinafoate
A G



AirDuo® RespiClick®
55/14, 113/14, 232/14 mcg
fluticasone propionate and salmeterol inhalation powder
A G



Breo® Ellipta®
50/25, 100/25, 200/25 mcg
fluticasone furoate and vilanterol inhalation powder
A C G



Breyna®
80/4.5, 160/4.5 mcg
budesonide and formoterol fumarate dihydrate (approved generic of Symbicort)
A C



Dulera®
50/5, 100/5, 200/5 mcg
mometasone furoate and formoterol fumarate dihydrate
A



Symbicort®
80/4.5, 160/4.5 mcg
budesonide and formoterol fumarate dihydrate
A C G



Wixela Inhub®
100/50, 250/50, 500/50 mcg
fluticasone propionate and salmeterol xinafoate (approved generic of Advair Diskus)
A C



contain LABA and long-acting muscarinic antagonist (LAMA)

Anoro® Ellipta®
62.5/25 mcg
umeclidinium and vilanterol inhalation powder
C



Bevespi Aerosphere®
9/4.8 mcg
glycopyrrolate and formoterol fumarate
C



Duakir® Pressair®
400/12 mcg
acridinium bromide and formoterol fumarate
C



Stiolto® RespiMat®
2.5/12.5 mcg
tiotropium bromide and olodaterol
C



contain ICS, LABA and LAMA

Trelegy® Ellipta®
200/62.5/25 mcg, 100/62.5/25 mcg
fluticasone furoate, umeclidinium and vilanterol inhalation powder
A C



Breztri Aerosphere®
160/9/4.8 mcg
budesonide, glycopyrrolate and formoterol fumarate
C



contain SABA and short-acting muscarinic antagonist (SAMA)

Combivent® RespiMat®
20/100 mcg
ipratropium bromide and albuterol
C



Ipratropium Bromide and Albuterol Sulfate Inhalation Solution
0.5mg/2.5mg; 3 mL
C G




BIOLOGICS

target cells and pathways that cause airway inflammation; delivered by injection or IV

Cinqair®
62.5/25 mL
reslizumab
A




Dupixent®
100, 200, 300 mg
dupilumab
A C



Fasenra®
30 mg
benralizumab
A



Nucala®
100 mg
mepolizumab
A



Tezspire®
210 mg
tezepelumab-ekko
A



Xolair®
75 to 375 mg
omalizumab
A



PDE3/4 INHIBITORS

control inflammation and reduce flare-ups

Ohtuvayre®
3 mg; 2.5 mL
enafentrine inhalation suspension
C N



PDE4 INHIBITORS

control inflammation and reduce flare-ups

Daliresp®
250, 500 mcg
roflumilast
C



LEUKOTRIENE MODIFIERS

block chemicals called leukotrienes that cause airway inflammation; available as tablet or granules

Singulair®
4, 5, 10 mg
montelukast
A



Zafirlukast
10, 20 mg
A



Zileuton
600 mg
A



Devices and Medications



Devices

pMDI



DPI



SoftMist



Nebulizer



pMDI



- Medication aerosolized by use of propellant
 - Currently HFA

pMDI



Pros

- Portable
- Quick to use
- No minimum peak inspiratory flow rate required
- Aerosolized by propellant
- Spacer

Cons

- Coordination required
- Deposition depends on technique
- Can be bulky if used with a spacer

Spacer



- Plastic holding chamber
- Multiple breaths
- Minimize coordination required
- Used with pMDI

Spacer



Pro

- Minimal coordination required
- Improved medication delivery
- Decreased particle size due to Brownian Motion

Cons

- Bulky
- Not all spacers are made the same
 - Per manufacturers' research
- Require cleaning

DPI



- Medication disaggregated and aerosolized by patient inspiratory effort
- Generally need > 30 – 60 LPM of patient generated inspiratory flow

DPI



Pros

- Small and portable
- Minimal coordination required
- No propellant needed

Cons

- Requires patient effort
- Requires patient to generate **significant** inspiratory flow
- Drug delivery depends on technique
- Not always feasible when SOB

SoftMist



- Aerosolization occurs due to the energy of a compressed spring
- Low velocity drug delivery
- Less coordination needed than pMDI
- Does not require high inspiratory flows
- Smaller particles
- Increase lung deposition
- Decrease oropharyngeal deposition

SoftMist



Pro

- Portable and compact
- Multidose
- Lower dependency on inspiratory effort
- High fine-particle fraction
- High lung deposition
- Low mouth and oropharynx deposition
- No propellant

Cons

- Coordination needed for actuation
- Not breath actuated
- Requires hand dexterity

Nebulizer



- Aerosol is generated by pressurized gas source or electricity
- Requires nebulizer machine or compressed gas source
- Takes 3–8 minutes depending on the medication(s) and flow

Nebulizer



Pros


- No patient coordination required
- Better insurance coverage
- Med delivery not dependent on technique

Cons

- TAKES time
- Not portable
- Requires outside energy source


Inhaler Imaging

A




Respimat SMI

B




Flexihaler DPI – Slow

C




Flexihaler DPI – Fast

D



pMDI

Pitcairn, G. et al., 2005




Determining Delivery Device

Questions to ask:

1. Is a deep, quick voluntary inhalation possible?
2. Can sufficient inspiratory flow be obtained?
3. Does the patient have sufficient hand–lung coordination?
4. What other inhaled medications is this patient taking? What devices are they already using?


Cataldo et al., 2022

Respiratory Device Decision Tree



Mahler, D. A., 2020

Respiratory Device Decision Tree



Kaplan & Price, 2018

Testing Inspiratory Flow Rate

- Post-it note test
- In-Check Dial
- Inhaler Noises



In Check Dial



- Measures inspiratory flow at various resistances



Inhaler Resistance Range



Alliance Tech Medical
PO Box 6024, Granbury, TX 76049
1.800.848.8923 / 817.326.6357 Fax: 817.326.2182
www.alliancetekmedical.com

©Copyright 2016 Clement Clarke International Ltd.

Part no. 3109306 Issue no. 3 Jan 17


Alliance
TECH MEDICAL



Using the In Check Dial

1. Set resistance to appropriate device
2. Place one way valve
3. Instruct patient on proper breathing technique
 - a. Quick for DPI
 - b. Slow for pMDI/SMI
4. Review where the red indicator finishes (should be in green zone)
5. Flow will change with different resistances

Link to demo videos & resources



Using an MDI

1. Prepare the device
2. Exhale completely (away from device)
3. Place inhaler between teeth
4. Seal lips around a mouthpiece
5. Actuate the device and breathe in SLOWLY
6. Take slow, deep breath
7. Hold breath (ideally 5–10 seconds)
8. Exhale

Using an MDI with a Spacer

1. Prepare the device
2. Place inhaler into the end of the spacer
3. Exhale completely (away from device)
4. Close mouth around mouthpiece of spacer
5. Actuate the device and breathe in SLOWLY
 - Some spacers may whistle if you breathe in too quickly
6. Take slow, deep breath
7. Hold breath (ideally 5–10 seconds)
8. Exhale

Using a DPI

1. Prepare the device (this varies on the device)
2. Breathe out completely – away from the device
3. Seal mouth around the mouth piece
 - Teeth should be open
4. Breathe in QUICKLY and deep
5. Hold breath for 5–10 seconds
6. Exhale

Using SoftMist

1. Prime inhaler
2. Breathe out completely – away from the device
3. Seal mouth around the mouth piece
4. Start taking a deep and steady breath as you push the button
5. Hold breath for 5–10 seconds
6. Exhale

Using a nebulizer

1. Assemble nebulizer
2. Place medication in nebulizer cup
3. Place mouthpiece in mouth or don facemask
4. Start nebulizer
5. Breathe normally until nebulizer begins to sputter

Order of Operations

1. Start with SABA
 - a. Especially if sick or wheezy
2. Move to controller meds
 - a. ESPECIALLY if using a DPI as controller

Key Points

- Respiratory medications are not a one size fits all
- Minimize the number of different devices
- Make sure medication delivery device matches patients needs
- Revisit patient's inhaler technique

References

- <https://www.uptodate.com/contents/inhaler-techniques-in-adults-beyond-the-basics/print>
- Cataldo, D., Hanon, S., Peché, R. V., Schuermans, D. J., Degryse, J. M, De Wulf, I. A., Elinck, K., Leys, M. H., Rummens, P. L., Derom, E. (2022). How to choose the right inhaler using a patient-centric approach? *Advanced Therapy*, 39, 1149–1163. <https://doi.org/10.1007/s12325-012-02034-9>
- Dalby, R. N., Eicher, J., Zierenberg, B. (2011). Development of Respimat® Soft Mist™ Inhaler and its clinical utility in respiratory disorders. *Medical Devices: Evidence and Research* <https://doi.org/10.2147/MDER.S7409>
- Kaplan, A., & Price, D. (2018). Matching inhaler devices with patients: The role of the primary care physician. *Canadian Respiratory Journal*, 2018. <https://doi.org/10.1155/2018/9473051>
- Mahler, D. A. (2020). The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. *Respiratory Medicine*. <https://doi.org/10.1016/j.rmed.2019.105857>